Report Details:
15 Companies Covered
80 Pages
Increasing Family Planning Awareness to Drive the Market at a CAGR of 6.3% During the Forecast Period 2025-2035
Ovulation Test Market Overview
The global ovulation test market witnessed steady expansion, fueled by rising awareness of reproductive health, an increasing number of first-time pregnancies at older ages, and growing cases of fertility-related disorders such as polycystic ovary syndrome (PCOS).
According to MRFR, the ovulation test market was valued at USD 2.87 billion in 2024 and is projected to reach USD 5.62 billion by 2035, registering a CAGR of 6.30% during the forecast period of 2025 to 2035.
Growing preference for home testing and self-monitoring solutions has greatly influenced market maturity, with consumers increasingly opting for convenient, user-friendly, and affordable testing kits available over the counter.
The widespread adoption of digital fertility tracking devices and the integration of mobile-app-based monitoring have further enhanced the appeal of ovulation testing, making it accessible beyond clinical settings.
The increasing focus on family planning and proactive fertility management reflects a shift in consumer behavior toward personalized healthcare and early self-diagnosis.
Segment Insights
Based on type, the market is segmented into urine-based tests, saliva-based tests, and other tests. Urine-based tests held the largest revenue share in 2022. This dominance is attributed to easy availability, widespread adoption of over-the-counter ovulation kits, and their high accuracy rate of around 99%.
These kits provide instant results and are convenient for at-home usage, which has significantly contributed to their sustained market leadership. Saliva-based tests also continue gaining traction due to their digital features and the reusable nature of the device, offering long-term cost benefits for frequent testing.
Based on the application segment, the market is segmented into hospitals, home care settings, clinics, and others. Home care settings accounted for the largest share of the market in 2022.
This trend is driven by consumers preferring privacy, convenience, and reduced dependence on clinical visits for routine ovulation tracking. The availability of test kits through retail stores, pharmacies, and online platforms further strengthens segment growth.
As acceptance of self-monitoring increases, at-home ovulation test kits continue to dominate demand, particularly in urban populations where women are prioritizing reproductive planning and lifestyle convenience.
Regional Insights
The study covers North America, Europe, Asia-Pacific, and the Rest of the World. North America dominated the ovulation test market in 2022, accounting for 45.80% of the total market share.
High consumer awareness regarding planned pregnancies, widespread availability of fertility testing kits, and growing adoption of digital testing devices drive strong regional performance.
The United States held the largest share in the region, while Canada represented the fastest-growing market due to rising awareness of fertility health and increasing adoption of over-the-counter ovulation kits.
Europe represents the second-largest market share. Rising public awareness regarding reproductive health, strong e-commerce penetration, and increasing access to ovulation testing tools support market expansion across Germany, France, and the United Kingdom.
In this region, Germany accounts for the largest share, while the United Kingdom shows the fastest growth. Asia-Pacific is expected to record significant growth through 2035.
This growth is attributed to rising awareness of family planning, increasing purchasing power, and rapid adoption of fertility management products in China, India, Japan, and Australia.
India is the fastest-growing market within this region, supported by a growing population of women of reproductive age and increasing e-commerce availability of testing kits.
Key Players
Key companies operating in the market include Fairhaven Health LLC, Fertility Focus Limited, NecLife, Swiss Precision Diagnostics GmbH, HiLin Life Products Inc., Geratherm Medical AG, Accuquik, Church & Dwight Co. Inc., Prestige Brands Holdings Inc., Clearblue, and Piramal Healthcare.
Industry Developments
- In February 2024, Clearblue (owned by Swiss Precision Diagnostics GmbH) introduced a new digital-connected ovulation testing solution on its official website, enabling users to sync results with fertility tracking mobile apps.
- In July 2024, Church & Dwight Co. Inc., the parent company of First Response, expanded its distribution partnership with major online pharmacy platforms, enhancing direct-to-consumer availability of ovulation and pregnancy test kits across North America.
Key Findings
- The ovulation test market was valued at USD 2.87 billion in 2024 and is projected to reach USD 5.62 billion by 2035. The market will grow at a CAGR of 6.30% between 2025 and 2035.
- Urine-based ovulation tests held the largest revenue share among product types in 2022.
- Home care settings dominated the application segment in 2022 due to increasing adoption of at-home testing.
- North America held 45.80% of the market share in 2022, making it the leading regional market.